Pneumosil (10-valent pneumococcal conjugate vaccine) / Serum Institute of India, Ligand - LARVOL DELTA

Pneumococcal vaccines: A dose of change. Vaccine failures and breakthrough infections in Belgian children during the PCV13 era (2019-2024). (PubMed, Vaccine) - "These findings provide the first national baseline of vaccine failures, offering a reference point for evaluating PCV20 introduction. Continued monitoring will be essential to assess the real-world impact of higher-valent pneumococcal vaccines and to guide evidence-based vaccination policy."

Journal • Infectious Disease • Pediatrics • Pneumococcal Infections • Pneumonia • Respiratory Diseases

Pneumococcal Vaccination of Adults in Italy: What Strategies? (PubMed, J Prev Med Hyg) - "In 2010, the 13-valent pneumococcal vaccine (PCV13) and 10-valent pneumococcal vaccine (PCV10) were approved...Regarding compliance, all possible strategies must be activated in order to raise public awareness of the risks of pneumococcal disease and the benefits of vaccination, so as to increase coverage rates. A thorough analysis of epidemiological and clinical data, combined with an assessment of the economic and social impact, is crucial to guiding vaccination policies and supporting efficient decision-making in order to protect the health of the entire population."

Journal • Infectious Disease • Pediatrics • Pneumococcal Infections • Pneumonia

Evolution of pneumococcal serotype 19A in children in Bangladesh: insights from genomic analysis. (PubMed, BMC Microbiol) - "This study presents the first comprehensive genomic analysis of the serotype 19A population in Bangladesh, supporting the decision to introduce PCV10 in Bangladesh based on local pneumococcal serotype burden data. However, the rapid evolution within the local 19A population highlights the need for continuous epidemiological and genomic surveillance to support effective vaccination programs."

Journal • Infectious Disease • Otorhinolaryngology • Pneumococcal Infections • Pneumonia

Safety and coverage of Pneumosil pneumococcal polysaccharide conjugate vaccine (10-valent PCV) in a camp for internally displaced persons in Somaliland. (PubMed, Vaccine) - P4 | "Vaccination of children PCV10-SII resulted in a small number of AEFIs. Campaign coverage suggests high acceptability of a newly introduced vaccine amongst IDPs in Somaliland."

Journal • Infectious Disease • Pneumococcal Infections

Large Reductions in Invasive Pneumococcal Disease and Related Morbidities Among Children in New Zealand After Change from PCV10 to PCV13. (PubMed, J Infect Dis) - "The timely change in pneumococcal vaccine and subsequent incidence decreases underscores the importance of epidemiology-driven decisions."

Journal • Infectious Disease • Pediatrics • Pneumococcal Infections

Population snapshot of Streptococcus pneumoniae causing invasive disease among adults aged ≥18 years in South Africa before and after implementation of pneumococcal conjugate vaccines in 2005-2020. (PubMed, Microb Genom) - "All GPSC9/CC63 isolates sequenced from the pre-PCV period (n=3) expressed serotype 14; however, during the late-PCV13 period, nearly all (88.2%, 15/17) were serotype 15A. The emergence among non-PCV13 serotypes, of lineages usually associated with PCV13 serotypes (such as GPSC5/CC172 and GPSC9/CC63), warrants continued genomic surveillance in South Africa, more so as PCV10 (Pneumosil) replaced PCV13 in South Africa in 2024."

Journal • Infectious Disease • Pneumococcal Infections • Pneumonia

Evolving pneumococcal epidemiology and vaccine impact in the Netherlands, 2004-2024: carriage and invasive disease. (PubMed, J Infect) - "This study shows stabilized pneumococcal carriage from 2018-2023 with low invasive disease potential for common serotypes, except for serotype 19A. However, rising IPD incidence from other non-vaccine serotypes highlights the need for higher-valency vaccines. The newly introduced PCV15 covers 58% of IPD cases, while PCV20 could cover 73%."

Journal • Infectious Disease • Pediatrics • Pneumococcal Infections • Pneumonia

Pneumococcal meningitis in Mexico. Serotype distribution and antimicrobial resistance before and after the introduction of pneumococcal conjugate vaccines in pediatric patients. Results from the GIVEBPVac group. (PubMed, J Infect Public Health) - "PCVs significantly reduced the burden of pneumococcal meningitis in Mexican children. However, the emergence of non-vaccine serotypes and the persistence of serotype 19 A highlights the need for continued surveillance and evaluation of higher-valent vaccines to inform future immunization strategies."

Journal • CNS Disorders • Infectious Disease • Pediatrics • Pneumococcal Infections • Pneumonia

Effectiveness of Pneumococcal Vaccines in Preventing Otitis Media in Children: A Targeted Literature Review (ISPOR-EU 2025) - "Median (range) of point VE estimates against all-cause OM/AOM across these three studies was 14% (2─27%) for PCV13 and 18% (5─42%) for PCV10; VE against pneumococcal OM was 86% for PCV13... This review supports the effectiveness of PCVs in reducing OM/AOM, particularly pneumococcal OM/AOM. However, evidence from RCTs is limited. VE estimates from observational studies vary substantially, likely due to heterogeneity in methodologies."

Clinical • Pneumococcal vaccines • Review • Infectious Disease • Otorhinolaryngology • Pneumococcal Infections

Impact of early life malaria chemoprevention on immunogenicity of pneumococcal vaccination in childhood (ASTMH 2025) - P3 | "While intermittent preventive treatment in childhood (IPTc) reduces malaria burden, its impact on immune responses to vaccines such as the pneumococcal conjugate vaccine (PCV-10; given at 6, 10, and 14 weeks in Uganda) remains unclear...IgG concentrations to all serotypes increased from week 8 to week 24, and from week 24 to week 52, in most but not all participants, indicating successful vaccine priming and boosting. Preliminary analyses also suggest differences by malaria exposure history; unblinded analyses by study arms will be shared at the meeting."

Clinical • Pneumococcal vaccines • Infectious Disease • Malaria • Pneumococcal Infections • Pneumonia • Respiratory Diseases

Pneumococcal Serotype Replacement in the Post-PCV Era: Implications for Vaccine Policy in Bangladesh (ASTMH 2025) - "Our findings show persistently low detection of PCV-10 serotypes even a decade after its introduction, while non-PCV-10 serotypes—particularly those covered by PCV-13 and PCV-20—continue to circulate widely in Bangladesh. This underscores the evolving pneumococcal serotype landscape and highlights the need for continuous surveillance to inform future vaccination strategies."

CNS Disorders • Infectious Disease • Pneumococcal Infections • Pneumonia • Respiratory Diseases • Septic Shock

Hospital-Based Surveillance of Pediatric Invasive Pneumococcal Diseases, 2016-2023 in Korea: Serotype Trends and Vaccination Policy. (PubMed, J Korean Med Sci) - "Given the approval of two new PCVs, the study results identified the substantial contribution of non-PCV13 serotypes to pediatric IPD and provide critical insights for optimal vaccination strategies to protect children against pneumococcal diseases."

Journal • Infectious Disease • Novel Coronavirus Disease • Pediatrics • Pneumococcal Infections • Pneumonia • Respiratory Diseases

Changing Landscape of Invasive Pneumococcal Disease Serotypes and Antimicrobial Resistance Following Pneumococcal Conjugate Vaccine Introduction in the Middle East and North Africa Region: A Systematic Review. (PubMed, Vaccines (Basel)) - "A decline in PCV7 serotypes was observed following the introduction of PCV10 or PCV13, which was more pronounced in PCV10-era studies...The study highlights the need for more robust surveillance across the region. Registration: CRD42018104529."

Journal • Review • Infectious Disease • Pneumococcal Infections • Pneumonia

Population Genetic Structure of Invasive and Non-Invasive Streptococcus pneumoniae Isolates After Fifteen Years of Routine PCV10 Vaccination in Bulgaria. (PubMed, Int J Mol Sci) - "The overall antimicrobial non-susceptibility rates were: benzylpenicillin (55.2%), ceftriaxone (15.2%), cefuroxime (35.8%), amoxicillin-clavulanic acid (38.8%), erythromycin (60.5%), clindamycin (57.0%), tetracycline (43.5%), trimethoprim-sulfamethoxazole (62.9%), and chloramphenicol (13.5%). Most serotype 3 isolates are associated with CC505, associated with Netherlands3-31 and GPSC12. Switching to a conjugate vaccine with broader serotype coverage could reduce the incidence of 19A, 6C, and 15A MDR S. pneumoniae clones in our country."

Journal • Infectious Disease • Pneumococcal Infections • Pneumonia

Changes in the Streptococcus pneumoniae population responsible for invasive disease of young children after the implementation of conjugated vaccines in the National Immunization Program in Poland. (PubMed, Vaccine) - "In the first three years after the introduction of the PCV10 into the Polish NIP significant reduction in the prevalence of PCV10-VTs was observed. Molecular characterization of the studied population allowed us to link the observed changes in the GPSC prevalence, with a decrease of infections caused by multi-drug resistant pneumococci and those with higher virulence associated with the presence of pili. The consistent evolution of S. pneumoniae influenced by population-based vaccinations, requires continuous surveillance."

Journal • Infectious Disease • Pneumococcal Infections • Pneumonia

Pneumococcal carriage prevalence, serotype distribution, and vaccine coverage in Ethiopia 12 years after pneumococcal vaccine introduction. (PubMed, Vaccine) - "There is considerable residual circulation of vaccine serotypes in Ethiopia, particularly in rural areas and the east, and low vaccine coverage. Pneumococcal epidemiology varies by geographical region and urban/rural setting, implying an unequal burden of pneumococcal disease across the country 12 years post-PCV introduction."

Journal • Infectious Disease • Pneumococcal Infections

Immunogenicity, safety and adverse events of sequential vaccination with a 10-valent pneumococcal conjugate vaccine (PCV10) and PPSV23 compared with PPSV23 alone in systemic lupus erythematosus. (PubMed, Lupus Sci Med) - "Both vaccination strategies are safe with adequate antibody response. In low- and middle-income countries, a single-dose PPSV23 may be adequate if cost negates sequential vaccination."

Adverse events • Clinical • Journal • CNS Disorders • Fatigue • Herpes Zoster • Immunology • Infectious Disease • Inflammatory Arthritis • Lupus • Migraine • Pain • Pneumococcal Infections • Rheumatology • Systemic Lupus Erythematosus • Varicella Zoster

Assessing the impact of childhood pneumococcal vaccination on pneumonia mortality in Colombia: a 14-year analysis. (PubMed, BMC Public Health) - "The 10-valent pneumococcal conjugate vaccine (PCV10) has been offered to all infants through Colombia’s National Immunization Program (NIP) since 2012, with catch-up vaccination until age 5...The findings underscore the need to expand pneumococcal vaccination programs to other age groups, mainly adults ≥ 60 years. The online version contains supplementary material available at 10.1186/s12889-025-23631-1."

Journal • Infectious Disease • Pediatrics • Pneumococcal Infections • Pneumonia • Respiratory Diseases

Impact of PCV10 Introduction on Nasopharyngeal Carriage of Streptococcus pneumoniae in Healthy Children in Rural and Urban Nepal (IDWeek 2025) - No abstract available

Clinical • Infectious Disease • Pneumococcal Infections

Interplay between maternal Tdap and infant pneumococcal vaccination in shaping infant pneumococcal vaccine serotype carriage. (PubMed, J Infect Dis) - P=N/A | "Tdap vaccination during pregnancy was associated with increased pneumococcal vaccine-related serotype carriage in infants, though the clinical significance remains uncertain. Future studies integrating vaccine serotype carriage data with protective pneumococcal antibody levels are needed to inform future maternal and infant vaccination strategies."

Journal • Infectious Disease • Pertussis • Pneumococcal Infections • Pneumonia • Respiratory Diseases • Tetanus

A decade of 10-valent pneumococcal conjugate vaccine use in Lithuania: trends in invasive pneumococcal serotype dynamics. (PubMed, Front Public Health) - "Lithuania introduced the 10-valent PCV (PCV10) into the National Immunization Program in 2014, with a subsequent switch to PCV15 in 2024...Limitations in current IPD surveillance hinder the ability of Lithuanian health authorities to make timely, evidence-based decisions regarding the impact of PCVs. Strengthening surveillance systems is essential to inform and guide effective pneumococcal vaccination strategies."

Journal • Infectious Disease • Pediatrics • Pneumococcal Infections • Pneumonia

Infant Malaria Vaccine Schedule Optimization (clinicaltrials.gov) - P2 | N=1200 | Recruiting | Sponsor: PATH | Trial completion date: Nov 2027 ➔ Mar 2028 | Trial primary completion date: Nov 2027 ➔ Mar 2028

Trial completion date • Trial primary completion date • Infectious Disease • Malaria

Effectiveness of a Single Dose of Pneumococcal Conjugate Vaccine Against Invasive Pneumococcal Disease in Children: A Systematic Literature Review. (PubMed, Infect Dis Ther) - "Available evidence demonstrates that a single dose of PCV provides protection against vaccine-type IPD, especially when administered after age 12 months. While complete vaccination according to licensed schedules provides optimal protection, our findings support single-dose catch-up programs for toddlers. Potential single-dose strategies for infants in humanitarian emergencies warrant further exploration."

Journal • Review • Infectious Disease • Pneumococcal Infections • Pneumonia

Cost-effectiveness of a 13-valent pneumococcal conjugate vaccine compared with currently available pneumococcal conjugate vaccines in Indian children. (PubMed, IJID Reg) - "This yielded incremental cost-effectiveness ratios (ICERs) for PCV13-PFE vs PCV10-SII and PCV10-GSK of INR 18,142 and INR 304,234 per QALY, respectively, both below the willingness-to-pay threshold of INR 590,949. PCV13-PFE was cost-saving compared to PCV14-BE. From the private sector perspective, vaccinating children in India with PCV13-PFE could prevent more PD cases, save more PD-associated medical costs, and be more cost-effective than other locally available PCV options."

HEOR • Journal • Infectious Disease • Pneumococcal Infections

Evaluation of Streptococcus pneumoniae as a cause of acute otitis media in Colombia: A prospective study. (PubMed, PLoS One) - "S. pneumoniae continues to be a leading cause of AOM in our country. Serotype 19A accounts for 67% of these infections and exhibits a multidrug-resistant pattern similar to that observed in invasive pneumococcal disease. These findings are consistent with international data and provide a baseline for tracking future AOM trends related to S. pneumoniae after the introduction of the PCV-13 vaccine."

Journal • Infectious Disease • Otorhinolaryngology • Pneumococcal Infections • Pneumonia